BACKGROUND: Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O-methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC. OBJECTIVE: In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task. STUDY DESIGN: We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083). SETTING: The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009. PATIENTS: Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated. INTERVENTION: Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH. MAIN OUTCOME MEASURE: Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors. RESULTS: There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing). CONCLUSION: Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.
RCT Entities:
BACKGROUND: Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O-methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC. OBJECTIVE: In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task. STUDY DESIGN: We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083). SETTING: The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009. PATIENTS: Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated. INTERVENTION: Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH. MAIN OUTCOME MEASURE: Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors. RESULTS: There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing). CONCLUSION: Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.
Authors: John G Kerns; Jonathan D Cohen; Angus W MacDonald; Melissa K Johnson; V Andrew Stenger; Howard Aizenstein; Cameron S Carter Journal: Am J Psychiatry Date: 2005-10 Impact factor: 18.112
Authors: M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger Journal: Proc Natl Acad Sci U S A Date: 2001-05-29 Impact factor: 11.205
Authors: Samuel R Chamberlain; Hanneke E M den Ouden; Vanessa Scholz; Roxanne W Hook; Mojtaba Rostami Kandroodi; Johannes Algermissen; Konstantinos Ioannidis; David Christmas; Stephanie Valle; Trevor W Robbins; Jon E Grant Journal: Neuropsychopharmacology Date: 2022-03-08 Impact factor: 8.294
Authors: Savita G Bhakta; Gregory A Light; Jo A Talledo; Bryan Balvaneda; Erica Hughes; Alexis Alvarez; Brinda K Rana; Jared W Young; Neal R Swerdlow Journal: Int J Neuropsychopharmacol Date: 2017-12-01 Impact factor: 5.678
Authors: Diego Santos García; Gustavo Fernández Pajarín; Juan Manuel Oropesa-Ruiz; Francisco Escamilla Sevilla; Raúl Rashid Abdul Rahim López; José Guillermo Muñoz Enríquez Journal: Brain Sci Date: 2022-03-12